Joost Kreijtz of Erasmus Medical Center will present at Influenza Congress USA on the development of their MVA-based pandemic influenza vaccine. He will speak on the preclinical evaluation of the vaccine and discuss the regulatory issues involved with the MVA platform.
Check out these two whitepapers, kindly provided by Joost, discussing the MVA based vaccine platform against the H5N1 virus, and some of the work taking place at Erasmus Medical Center with recombinants and the H5N1 virus.
The first whitepaper, entitled â€˜Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques,’ looks at the Erasmus MVA H5N1 vaccine study, and how this could be a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.
The second whitepaper, entitled â€˜MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization,’ looks at a study on mice that suggests that MVA-based vaccines allows significant dose-sparing and affords cross-clade protection.
Erasmus has been at the forefront of influenza vaccine research and development. You cannot miss this discussion at Influenza Congress USA! Register now to confirm your seat.